Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 11, 2019
Agreement to jointly commercialise the new diabetic kidney disease (DKD) indication for INVOKANA® (canagliflozin) in the US Only diabetes treatment indicated to slow down the progression of DKD...
-
Apr 9, 2019Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...
-
Mar 26, 2019CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®
26 Mar 2019 Hizentra® [human normal immunoglobulin, 20%, subcutaneous] is the first and only subcutaneous immunoglobulin approved for the maintenance treatment of CIDP in Japan, based on findings...
-
Mar 15, 2019
MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...
-
Mar 14, 2019
VIFOR PHARMA GROUP REPORTS STRONG 2018 RESULTS, EXCEEDING RAISED GUIDANCE THE VIFOR PHARMA GROUP REPORTED A STRONG SALES AND PROFIT PERFORMANCE IN 2018 WITH CONTINUED SOLID GROWTH FROM ITS THREE...
-
Feb 4, 2019Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
04 Feb 2019 MONTREAL and KING OF PRUSSIA, Pa. – 4 February 2019 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has...
-
Jan 24, 2019
Companies plan to file for full marketing approval to EMA and FDA in 2020 MOUNTAIN VIEW, Calif. and ZURICH, 24 January, 2019 – ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma...
-
Jan 22, 2019
Re-analysis of the PIVOTAL data by the investigators has revealed that proactive, high-dose Venofer® compared to reactive, low-dose Venofer® resulted in: Superiority and statistically...
-
Jan 16, 2019Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019
16 Jan 2019 KING OF PRUSSIA, Pa. – January 16, 2019 – Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL,...
-
Jan 14, 2019
This news release is intended for Health Professional media only. Seqirus to launch its cell-based influenza vaccine in Europe for the 2019-20 season Real-world data indicates cell-based influenza...
-
Jan 7, 2019CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.
07 Jan 2019 King of Prussia, Pa – Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, today announced that...
-
Dec 14, 2018
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...
-
Dec 12, 2018
Vifor Pharma Group is pleased to announce the appointment of Patrick Treanor as President of Relypsa on a permanent basis. He is also appointed to the Executive Committee of Vifor Pharma Group...
-
Dec 6, 2018Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
06 Dec 2018 KING OF PRUSSIA, Pa. – December 6, 2018 – Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal’s Most Admired CEOs for 2018,...
-
Dec 5, 2018
CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real-world...
-
Nov 26, 2018
This year’s Iron Deficiency Day (26 November 2018) aims to raise awareness of the serious public health problems posed by iron deficiency and iron deficiency anaemia and highlight the negative...
-
Nov 16, 2018
This news release is intended for Health Professional media only. 16 Nov 2018 Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that...
-
Nov 16, 2018
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets. 16 Nov 2018 Seqirus, a...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Oct 29, 2018
PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER FERRITIN...
-
Oct 22, 2018Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region
22 Oct 2018 PHILADELPHIA, Pa. – October 22, 2018 – The University City Science Center and global biotechnology leader CSL Behring, which has its operational headquarters in King of Prussia,...
-
Oct 22, 2018ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency
22 Oct 2018 LISBON, Portugal – 22 October 2018 – Global biotherapeutics leader CSL Behring today announced that it will host a panel of cross-specialty experts at its “Current and Emerging...
-
Oct 19, 2018
Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season. 19 Oct 2018 Seqirus, a global leader in...
-
Oct 11, 2018
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we...